Pulmozyme Market Revenue Growth Forecast To Reach $2.09 Billion By 2030 At 10.7% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Pulmozyme Market Progress Between 2026 And 2030?

The notable expansion observed historically was a consequence of proven effectiveness in addressing alpha-1 antitrypsin deficiency, backing from pulmonology guidelines, the accessibility of plasma-derived proteins, prevailing specialist prescribing trends, and advancements in disease management leading to better outcomes.

The expansion projected for the forecast period stems from the proliferation of genetic screening programs, the escalating prevalence of COPD, the broadening scope of specialized respiratory care, improved adherence among patients, and the development of plasma collection infrastructure. Significant trends anticipated during the forecast span include the growing acceptance of augmentation therapy, a concerted effort to hinder COPD progression, the sustained use of long-term plasma protein replacement, administration primarily within hospitals and specialty clinics, and an increasing understanding of genetic lung disorders.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19923&type=smp

Which Strong Drivers Are Impacting The Pulmozyme Market Growth?

The projected expansion of the pulmozyme market is linked to an increase in respiratory disorders. These conditions, which compromise breathing and oxygen exchange by affecting the lungs and airways, encompass ailments like asthma, COPD, and pneumonia. Factors contributing to the rise in respiratory illnesses include growing air pollution, smoking, workplace dangers, shifts in climate, and a greater occurrence of allergens and infectious diseases. Pulmozyme (dornase alfa) helps address respiratory conditions such as cystic fibrosis by dissolving thick mucus in the lungs, thereby enhancing airflow and lessening the likelihood of infections. An example of this trend is seen in Australia, where the Australian Institute of Health and Welfare, a health and welfare agency, reported in June 2024 that around 8.5 million individuals, representing 34% of the population, were believed to suffer from chronic respiratory conditions. Among these, an estimated 2.8 million people, or 11% of the population, had asthma, and 638,000 people, or 2.5% of the population, were living with chronic obstructive pulmonary disease (COPD). Consequently, the growing incidence of respiratory disorders is a key impetus for the pulmozyme market. The pulmozyme market also sees momentum from a growing number of lung transplants. A lung transplant involves replacing a diseased or non-functioning lung with a healthy one from a donor, typically to address severe respiratory failure or long-term lung conditions. The growth in these procedures can be attributed to a higher incidence of chronic respiratory ailments like cystic fibrosis and COPD, alongside enhanced surgical methods and improvements in care following transplantation that boost survival rates. Pulmozyme, a recombinant human DNase enzyme, benefits lung transplant recipients by dissolving dense, adhesive mucus in their airways, thereby lowering the chances of infection and enhancing lung performance. This ultimately assists them in breathing better and sustaining respiratory health after the transplant. As an illustration, the National Health Service (NHS), a UK-based healthcare system, reported in August 2023 that the count of UK residents living with active lung and heart-lung transplants rose from 267 in 2022 to 302 in 2023. Thus, the growing number of lung transplants is a significant factor propelling the pulmozyme market.

How Is The Pulmozyme Market Organized By Segment Classification?

The pulmozyme market covered in this report is segmented –

1) By Indication: Cystic Fibrosis, Respiratory Tract Infections

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By End User: Hospitals And Clinics, Homecare Settings

Which Trends Are Shaping Growth In The Pulmozyme Market?

Leading firms within the cystic fibrosis treatment device market are concentrating on creating sophisticated options, including vibrating mesh nebulizers, with the goal of improving medication administration, boosting patient compliance, and enhancing overall patient well-being. These vibrating mesh nebulizers are instruments that employ a delicate mesh to produce a steady aerosol, facilitating a more effective and precise administration of drugs such as Pulmozyme directly to the lungs. Illustratively, in March 2024, HCmed, a medical technology firm headquartered in Taiwan, disclosed that its Pulmogine Vibrating Mesh Nebulizer gained FDA clearance for administering Pulmozyme, positioning it as one of merely five FDA-approved mesh nebulizer units suitable for this treatment. This clearance highlights the market’s emphasis on inventive delivery systems designed to maximize treatment results and elevate the patient journey.

Who Are The Industry Participants Involved In The Pulmozyme Market?

Major companies operating in the pulmozyme market are Roche Holding AG

Get The Full Pulmozyme Market Report:

https://www.thebusinessresearchcompany.com/report/pulmozyme-global-market-report

Which Region Is The Top Contributor To The Pulmozyme Market By Share?

North America was the largest region in the pulmozyme market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmozyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pulmozyme Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pulmozyme-global-market-report

Browse Through More Reports Similar to the Global Pulmozyme Market 2026, By The Business Research Company

Pulmonologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonologists-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Pyrethroids Market Report 2026

https://www.thebusinessresearchcompany.com/report/pyrethroids-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795